CONFIDENTIALITY AGREEMENTConfidentiality Agreement • December 27th, 2019 • Sanofi • Pharmaceutical preparations • Delaware
THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of December 3, 2019, between SYNTHORX, INC., a Delaware corporation (the “Company”), and SANOFI, a French corporation (“Counterparty”).
Offer To Purchase All Outstanding Shares of Common Stock of SYNTHORX, INC. at $68.00 Per Share, Net in Cash by THUNDER ACQUISITION CORP., a wholly owned indirect subsidiary of SANOFIOffer to Purchase • December 27th, 2019 • Sanofi • Pharmaceutical preparations • Delaware
The information contained in this summary term sheet is a summary only and is not meant to be a substitute for the more detailed description and information contained in the remainder of this Offer to Purchase, the Letter of Transmittal and the Notice of Guaranteed Delivery. You are urged to read carefully this Offer to Purchase, the Letter of Transmittal and the Notice of Guaranteed Delivery in their entirety. This summary term sheet includes cross-references to other sections of this Offer to Purchase where you will find more complete descriptions of the topics mentioned below. The information concerning the Company contained in this summary term sheet and elsewhere in this Offer to Purchase has been provided to Parent and Purchaser by the Company or has been taken from, or is based upon, publicly available documents or records of the Company on file with the Securities and Exchange Commission (the “SEC”) or other public sources at the time of the Offer. Parent and Purchaser have not
EXCLUSIVITY AGREEMENTExclusivity Agreement • December 27th, 2019 • Sanofi • Pharmaceutical preparations • Delaware
This Exclusivity Agreement (this “Agreement”) is entered into as of December 3, 2019, by and between Synthorx Inc, a Delaware corporation (the “Company”) and Sanofi (with its affiliates, “Counterparty”).
